Can a new interferon tame hepatitis d?
Disease control
Completed
This phase 2 trial tests whether peginterferon lambda, an experimental interferon drug, can safely reduce hepatitis D virus levels in people with chronic infection. Participants receive one of two doses of the drug for 48 weeks, and researchers measure changes in viral load and l…
Phase 2 • Sponsor: EIT Pharma, Inc. • Aim: Disease control
Last updated Sep 09, 2026 21:00 UTC